Cencora, Inc. (COR) shareholders
CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 14/3022% above fair value
$349.38−0.50 (-0.14%)
Close on Nov 12, 2026Market cap $66.67BP/E 25.9Yield 0.63%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
96.1%
183M of 191M shares
Institutional holders
1,344
108 new, 179 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
3 buys · 13 sales
Net sold $13.07M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 16,405,771 | 8.50% | 13G (passive) amendment | Dec 31, 2024 |
| Vanguard Capital Management | 14,210,260 | 7.30% | 13G (passive) | Mar 31, 2026 |
| Walgreens Boots Alliance, Inc. Joint filing with Walgreens Boots Alliance Holdings LLC (5.40%), WBA Investments, Inc. (5.40%) | 10,380,000 | 5.40% | 13D (active) amendment | May 27, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,213,783 | 9.54% | $5.15B | −1,729,854 | 0.08% |
| Vanguard Capital Management LLC | 12,378,943 | 6.49% | $3.50B | +65,484 | 0.07% |
| Vanguard Portfolio Management LLC | 9,611,756 | 5.04% | $2.72B | +21,342 | 0.12% |
| State Street Corp | 9,273,983 | 4.86% | $2.62B | +83,432 | 0.08% |
| T. Rowe Price Investment Management, Inc. | 7,410,910 | 3.88% | $2.10B | +1,116,614 | 1.37% |
| Price T Rowe Associates Inc /Md/ | 7,132,687 | 3.74% | $2.02B | −191,019 | 0.20% |
| JPMorgan Chase & Co | 5,943,657 | 3.11% | $1.67B | +1,058,179 | 0.09% |
| Geode Capital Management, LLC | 5,454,888 | 2.86% | $1.54B | −111,156 | 0.08% |
| Boston Partners | 4,868,782 | 2.55% | $1.38B | +385,965 | 1.23% |
| Wellington Management Group Llp | 4,559,761 | 2.39% | $1.29B | +11,149 | 0.22% |
| FMR LLC | 4,122,371 | 2.16% | $1.17B | −2,563,898 | 0.05% |
| Morgan Stanley | 4,086,271 | 2.14% | $1.16B | −445,641 | 0.06% |
| Bank Of America Corp /De/ | 3,733,921 | 1.96% | $1.06B | −404,467 | 0.07% |
| Norges Bank | 2,473,825 | 1.30% | $700.04M | New | 0.07% |
| Goldman Sachs Group Inc | 2,274,148 | 1.19% | $643.54M | +61,260 | 0.06% |
| Amundi | 2,229,326 | 1.17% | $630.85M | +676,066 | 0.15% |
| Northern Trust Corp | 2,158,939 | 1.13% | $610.94M | −23,736 | 0.07% |
| Invesco Ltd. | 2,021,234 | 1.06% | $571.97M | −1,966,502 | 0.05% |
| Capital Research Global Investors | 1,979,942 | 1.04% | $560.28M | +20,292 | 0.08% |
| Carmignac Gestion | 1,747,363 | 0.92% | $494.46M | +646,112 | 6.42% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,344 | 183M | 96.1% | 108 / 434 | 618 / 179 | 19M | 18M |
| Q1 2026 | 1,435 | 183M | 95.9% | 136 / 530 | 544 / 146 | 36M | 17M |
| Q4 2025 | 1,470 | 188M | 98.5% | 229 / 499 | 534 / 89 | 24M | 19M |
| Q3 2025 | 1,358 | 184M | 96.3% | 137 / 538 | 453 / 103 | 21M | 16M |
| Q2 2025 | 1,347 | 186M | 97.7% | 172 / 501 | 469 / 97 | 20M | 20M |
| Q1 2025 | 1,291 | 187M | 98.2% | 193 / 439 | 480 / 108 | 17M | 22M |
| Q4 2024 | 1,228 | 195M | 100.0% | 177 / 480 | 392 / 90 | 11M | 15M |
| Q3 2024 | 1,163 | 201M | 100.0% | 131 / 468 | 389 / 88 | 32M | 16M |
| Q2 2024 | 1,133 | 203M | 100.0% | 102 / 450 | 405 / 113 | 12M | 19M |
| Q1 2024 | 1,154 | 210M | 100.0% | 172 / 393 | 423 / 86 | 43M | 11M |
| Q4 2023 | 1,080 | 179M | 93.6% | 190 / 351 | 403 / 72 | 24M | 10M |
| Q3 2023 | 974 | 164M | 86.1% | 101 / 343 | 368 / 119 | 13M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
984 funds held COR in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of COR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,867,758 | 3.07% | $1.66B | 0.07% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 5,041,886 | 2.64% | $1.43B | 0.09% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 4,437,584 | 2.33% | $1.26B | 1.78% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 4,005,017 | 2.10% | $1.13B | 0.51% | Jun 30, 2026 |
| Vanguard Health Care Fund | 3,033,825 | 1.59% | $944.55M | 2.47% | Jul 31, 2026 |
| iShares Core S&P 500 ETF | 2,676,128 | 1.40% | $757.29M | 0.09% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 2,489,416 | 1.30% | $670.55M | 0.08% | May 31, 2026 |
| Vanguard Value Index Fund | 1,758,393 | 0.92% | $497.59M | 0.20% | Jun 30, 2026 |
| Fidelity Magellan Fund | 1,554,051 | 0.81% | $439.77M | 1.16% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,374,447 | 0.72% | $388.94M | 0.96% | Jun 30, 2026 |
| T. Rowe Price Value Fund, Inc. | 1,202,600 | 0.63% | $340.31M | 1.00% | Jun 30, 2026 |
| Vanguard Mid-Cap Value Index Fund | 1,187,155 | 0.62% | $335.94M | 0.90% | Jun 30, 2026 |
| Investment Co of America | 1,146,598 | 0.60% | $324.46M | 0.18% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 1,102,109 | 0.58% | $311.87M | 1.45% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 1,100,813 | 0.58% | $342.73M | 0.26% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert P. Mauch | President & CEO, Director | 67,786 | 0.04% | Nov 10, 2026 |
| Steven H. Collis | Executive Chairman, Director | 305,913 | 0.16% | Sep 18, 2025 |
| Lazarus Krikorian | SVP & Chief Accounting Officer | 15,019 | 0.01% | Nov 10, 2026 |
| Elizabeth S. Campbell | Executive Vice President | 20,439 | 0.01% | Nov 10, 2026 |
| Pawan Verma | EVP, Chief Data & Info Officer | 9,432 | 0.00% | Nov 3, 2026 |
| Silvana Battaglia | Executive Vice President | 23,624 | 0.01% | Jul 7, 2026 |
| Eva C. Boratto | Chief Financial Officer | 3 | 0.00% | Jun 30, 2026 |
| James F. Cleary | Chief Financial Officer | 160,363 | 0.08% | Mar 13, 2026 |
| Lauren M. Tyler | Director | 4,547 | 0.00% | Nov 3, 2026 |
| Ellen Cooper | Director | 984 | 0.00% | Nov 3, 2026 |
| Dennis M. Nally | Director | 13,294 | 0.01% | Nov 3, 2026 |
| Robert E. Sanchez | Director | 472 | 0.00% | Oct 5, 2026 |
| Lon R. Greenberg | Director | 17,128 | 0.01% | Sep 17, 2026 |
| Dermot Mark Durcan | Director | 31,767 | 0.02% | Jun 22, 2026 |
| Lori Ryerkerk | Director | 1,073 | 0.00% | Mar 9, 2026 |
| Lorence H. Kim | Director | 4,249 | 0.00% | Mar 9, 2026 |
| Redonda Miller | Director | 3,751 | 0.00% | Mar 9, 2026 |
| Werner Baumann | Director | 3,687 | 0.00% | Mar 9, 2026 |
| Frank Clyburn | Director | 1,724 | 0.00% | Mar 9, 2026 |
| Boots Alliance Holdings LLC Walgreens | 10% owner | 16,738,979 | 8.77% | Feb 10, 2025 |
| Walgreens Boots Alliance, Inc. | 10% owner | 26,277,561 | 13.77% | Feb 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Elizabeth S. Campbell Executive Vice President | Nov 6, 2026 | Tax withholding | −846 | $333.56 | $282.19K | 20,439 |
| Elizabeth S. Campbell Executive Vice President | Nov 6, 2026 | Option exercise | +1,830 | – | – | 21,285 |
| Robert P. Mauch President & CEO, Director | Nov 6, 2026 | Tax withholding | −1,673 | $333.56 | $558.05K | 67,786 |
| Robert P. Mauch President & CEO, Director | Nov 6, 2026 | Option exercise | +4,066 | – | – | 69,459 |
| Lazarus Krikorian SVP & Chief Accounting Officer | Nov 6, 2026 | Tax withholding | −576 | $333.56 | $192.13K | 15,019 |
| Lazarus Krikorian SVP & Chief Accounting Officer | Nov 6, 2026 | Option exercise | +1,398 | – | – | 15,595 |
| Lazarus Krikorian SVP & Chief Accounting Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −986 | $330.96 | $326.33K | 14,197 |
| Lauren M. Tyler Director | Oct 30, 2026 | Award | +91 | $330.84 | $30.11K | 4,547 |
| Dennis M. Nally Director | Oct 30, 2026 | Award | +106 | $330.84 | $35.07K | 13,294 |
| Pawan Verma EVP, Chief Data & Info Officer | Oct 30, 2026 | Tax withholding | −4,254 | $330.84 | $1.41M | 9,432 |
| Pawan Verma EVP, Chief Data & Info Officer | Oct 30, 2026 | Option exercise | +8,538 | – | – | 13,686 |
| Ellen Cooper Director | Oct 30, 2026 | Award | +91 | $330.84 | $30.11K | 984 |
| Lazarus Krikorian SVP & Chief Accounting Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −986 | $303.18 | $298.94K | 15,183 |
| Robert E. Sanchez Director | Oct 1, 2026 | Award | +275 | – | – | 275 |
| Lon R. Greenberg Director | Sep 16, 2026 | Sale | −1,280 | $321.30 | $411.26K | 17,128 |
| Lazarus Krikorian SVP & Chief Accounting Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −985 | $325.97 | $321.08K | 16,169 |
| Elizabeth S. Campbell Executive Vice President | Aug 24, 2026 | Sale | −11,300.47 | $324.12 | $3.66M | 19,455 |
| Dennis M. Nally Director | Jul 31, 2026 | Award | +113 | $311.34 | $35.18K | 13,188 |
| Ellen Cooper Director | Jul 31, 2026 | Award | +97 | $311.34 | $30.20K | 893 |
| Lauren M. Tyler Director | Jul 31, 2026 | Award | +97 | $311.34 | $30.20K | 4,456 |
| Elizabeth S. Campbell Executive Vice President | Jun 30, 2026 | Award | +49.89 | $240.53 | $12.00K | 30,756 |
| Silvana Battaglia Executive Vice President | Jun 30, 2026 | Award | +58.2 | $240.53 | $14.00K | 23,624 |
| Lauren M. Tyler Director | Jun 22, 2026 | Buy | +550 | $270.23 | $148.63K | 4,359 |
| Dermot Mark Durcan Director | Jun 18, 2026 | Buy | +4,000 | $274.19 | $1.10M | 31,767 |
| Dermot Mark Durcan Director | May 28, 2026 | Buy | +4,000 | $266.26 | $1.07M | 27,767 |
| Dennis M. Nally Director | May 1, 2026 | Award | +116 | $304.00 | $35.26K | 13,075 |
| Lauren M. Tyler Director | May 1, 2026 | Award | +99 | $304.00 | $30.10K | 3,809 |
| Ellen Cooper Director | May 1, 2026 | Award | +99 | $304.00 | $30.10K | 796 |
| Elizabeth S. Campbell Executive Vice President | Mar 11, 2026 | Tax withholding | −5,842 | $350.30 | $2.05M | 30,706 |
| Elizabeth S. Campbell Executive Vice President | Mar 11, 2026 | Option exercise | +12,623 | – | – | 36,548 |
| Silvana Battaglia Executive Vice President | Mar 11, 2026 | Option exercise | +8,415 | – | – | 27,239 |
| Silvana Battaglia Executive Vice President | Mar 11, 2026 | Tax withholding | −3,673 | $350.30 | $1.29M | 23,566 |
| James F. Cleary Chief Financial Officer | Mar 11, 2026 | Tax withholding | −5,409 | $350.30 | $1.89M | 160,357 |
| James F. Cleary Chief Financial Officer | Mar 11, 2026 | Option exercise | +12,623 | – | – | 165,766 |
| Lauren M. Tyler Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 3,710 |
| Ellen Cooper Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 697 |
| Lori Ryerkerk Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 1,073 |
| Redonda Miller Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 3,751 |
| Frank Clyburn Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 1,724 |
| Lon R. Greenberg Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 18,408 |
| Werner Baumann Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 3,687 |
| Dermot Mark Durcan Director | Mar 5, 2026 | Award | +905 | $359.28 | $325.15K | 23,767 |
| Dennis M. Nally Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 12,959 |
| Lorence H. Kim Director | Mar 5, 2026 | Award | +557 | $359.28 | $200.12K | 4,081 |
| Robert P. Mauch President & CEO, Director | Feb 20, 2026 | Option exercise | +3,762 | $86.09 | $323.87K | 69,155 |
| Robert P. Mauch President & CEO, Director | Feb 20, 2026 | Sale(10b5-1 plan) | −3,762 | $358.94 | $1.35M | 65,393 |
| Robert P. Mauch President & CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −1,333 | $359.46 | $479.16K | 65,393 |
| Lauren M. Tyler Director | Jan 30, 2026 | Award | +84 | $359.22 | $30.17K | 3,153 |
| Ellen Cooper Director | Jan 30, 2026 | Award | +69 | $359.22 | $24.79K | 74 |
| Ellen Cooper Director | Jan 30, 2026 | Award | +66 | $359.22 | $23.71K | 140 |
| Dennis M. Nally Director | Jan 30, 2026 | Award | +98 | $359.22 | $35.20K | 12,402 |
| Robert P. Mauch President & CEO, Director | Jan 20, 2026 | Option exercise | +3,763 | $86.09 | $323.96K | 71,822 |
| Robert P. Mauch President & CEO, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −5,096 | $354.73 | $1.81M | 66,726 |
| Elizabeth S. Campbell Executive Vice President | Dec 31, 2025 | Award | +33.53 | $287.09 | $9.63K | 23,925 |
| Silvana Battaglia Executive Vice President | Dec 31, 2025 | Award | +27.34 | $287.09 | $7.85K | 18,824 |
| Silvana Battaglia Executive Vice President | Dec 19, 2025 | Sale | −1,677 | $345.00 | $578.57K | 18,796 |
| Elizabeth S. Campbell Executive Vice President | Dec 19, 2025 | Sale | −3,351 | $342.10 | $1.15M | 23,891 |
| Robert P. Mauch President & CEO, Director | Dec 18, 2025 | Option exercise | +3,763 | $86.09 | $323.96K | 73,155 |
| Robert P. Mauch President & CEO, Director | Dec 18, 2025 | Sale(10b5-1 plan) | −5,096 | $343.45 | $1.75M | 68,059 |
| James F. Cleary Chief Financial Officer | Dec 17, 2025 | Tax withholding | −26,952 | $344.15 | $9.28M | 153,143 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.75%
3M shares short
Days to cover
2.6
At 1M shares a day
Change since last report
-19.7%
From 4M shares
Short volume, 20 days
41.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cencora's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,747 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lon R. Greenberg Director | Sep 16, 2026 | 1,280 | $411.28K | Sep 16, 2026 | Director Compensation |
| Silvana Battaglia Former Officer | Sep 11, 2026 | 1,324 | $430.30K | Sep 11, 2026 | Restricted Stock Vesting |
| James F. Cleary Former Officer | Sep 4, 2026 | 10,000 | $3.35M | Sep 4, 2026 | Option Granted |
| Silvana Battaglia Former Officer | Sep 1, 2026 | 6,593 | $2.18M | Sep 1, 2026 | Restricted Stock Vesting |
| Elizabeth S. Campbell Officer | Aug 24, 2026 | 11,301 | $3.66M | Aug 24, 2026 | ESPP Purchase |
| James F. Cleary Officer | Aug 6, 2026 | 20,000 | $6.33M | Aug 6, 2026 | Restricted Stock Vesting |
| Robert P. Mauch Officer, Director | Feb 20, 2026 | 3,762 | $1.35M | Feb 20, 2026 | Option Granted - 11/13/2019 |
| Robert P. Mauch Officer, Director | Feb 18, 2026 | 1,333 | $479.16K | Feb 18, 2026 | Restricted Stock Vesting |
| Robert P. Mauch Officer, Director | Jan 20, 2026 | 5,096 | $1.81M | Jan 20, 2026 | Restricted Stock Vesting |
| Elizabeth S. Campbell Officer | Dec 19, 2025 | 3,351 | $1.15M | Dec 19, 2025 | Restricted Stock Vesting |
| Silvana Battaglia Officer | Dec 19, 2025 | 1,677 | $578.57K | Dec 19, 2025 | Restricted Stock Vesting |
| Robert P. Mauch Officer, Director | Dec 18, 2025 | 5,096 | $1.75M | Dec 18, 2025 | Restricted Stock Vesting |
| Lazarus Krikorian Officer | Dec 17, 2025 | 4,031 | $1.38M | Dec 17, 2025 | Restricted Stock Vesting |
| Robert P. Mauch Officer, Director | Nov 18, 2025 | 5,096 | $1.87M | Nov 18, 2025 | Restricted Stock Vesting |
| Steven H. Collis Former Officer & Director | Nov 18, 2025 | 31,349 | $11.49M | Nov 18, 2025 | Restricted Stock Vesting |
See a number that looks wrong?